TB 402

Drug Profile

TB 402

Alternative Names: Anti factor VIII monoclonal antibody LE 2E9; Mab LE 2E9; TB-402; TGX Krix-1

Latest Information Update: 11 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Leuven
  • Developer BioInvent International; ThromboGenics
  • Class Anticoagulants; Antithrombotics; Monoclonal antibodies
  • Mechanism of Action Factor VIII inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Venous thromboembolism

Most Recent Events

  • 10 Sep 2018 Thrombogenics is now called Oxurion
  • 05 Jun 2012 Discontinued - Phase-II for Venous thromboembolism in European Union (IV, Infusion)
  • 05 Jun 2012 Discontinued - Phase-II for Venous thromboembolism in European Union (IV, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top